O'Shares富時美國優質紅利ETF OUSA 深 滬
等待開盤 12-12 09:30:00 美东时间
57.85
+0.500
+0.87%
華盛通- 最 高57.9465
- 今 開57.47
- 成交量 3.56万股
- 最 低 57.47
- 昨 收 57.35
- 總市值 8.72亿
- 52周最高 57.9465
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 46.6639
- 委 比 -85.71%
- 總股本 1507.50万
- 歷史最高 57.9465
- 量 比 2.30
- 振 幅 0.83%
- 歷史最低 13.6749
- 每 手 1
- 風險率 1.95%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMG THOUSAND OAKS, C...
今天 07:09
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
THOUSAND OAKS, Calif., Dec. 9, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026. The div...
12-10 05:01
Sean Duffy Says Tim Walz Has 30 Days To Rectify Discrepancies Or Lose $30 Million In Federal Funds Amid Illegal CDL Row: 'Fix This Or…'
Transportation Secretary Sean Duffy slams MN governor Tim Walz for issuing illegal CDLs, threatens to pull $30M in funds.
12-02 14:05
Reported November 19, 2025: Amgen's IMDELLTRA Receives FDA Approval For Extensive Stage Small Cell Lung Cancer After Phase 3 Trial Shows 40% Reduction In Death Risk Compared To Chemotherapy
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to ChemotherapyUnderscores IMDELLTRA as a Recognized Standard of Care Treatment for Patients With Extensive Stage Small
11-20 22:45
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025. The d...
11-01 04:01
Amgen To Present New Data From Cardiovascular Portfolio, Including Late-Breaking Results From Phase 3 VESALIUS-CV Clinical Trial Of Repatha, At AHASS 2025
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or StrokeReal-World Evidence from the Repatha-CE Trial Reinforces Its
10-31 21:03
Amgen Announces FDA Approval Of TEZSPIRE For Chronic Rhinosinusitis With Nasal Polyps In Patients Aged 12 And Older, Expands Use To Second Epithelial-Driven Disease
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation
10-18 04:02
Amgen Announces The Phase 3 VESALIUS-CV Clinical Trial Met Its Dual Primary Endpoints Demonstrating That Repatha Significantly Reduced The Risk Of Major Adverse Cardiovascular Events In Individuals Without A Prior History Of Heart Attack Or Stroke
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy AloneRepatha is Now the First and Only PCSK9 Inhibitor to
10-02 21:18
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
THOUSAND OAKS, Calif., Sept. 26, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs. The plan...
09-26 21:00
Amgen To Invest Over $600M In New U.S. Science And Innovation Center, Creating Hundreds Of Jobs
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs THOUSAND OAKS, Calif., Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to invest more than $600
09-02 21:04
